Three companies to expand market presence of new diabetes combo agent

Three drug makers – Boehringer Ingelheim Korea, Lilly Korea and Yuhah Corp. – announced Tuesday that they will expand the market presence of Tranjenta Duo, a combination tablet of dipeptidyl peptidase-4 (DPP-4) inhibitor Trajenta (linagliptin) and metformin offering strong glycaemic control across glycosylated haemoglobin levels (HbA1c).

In a press interview commemorating the combination’s l...